Abstract
Summary: During the World Conference on Lung Cancer (WCLC) 2020, which took place virtually 28-31. January 2021, the results of a number of clinical studies focused on bronchogenic carcinoma and other thoracic malignancies were presented.
Immunotherapy continues to confirm its place in the first-line treatment of non-small cell lung cancer (NSCLC), even in combination with other treatment modalities. The shift of immunotherapy to lower stages of the disease is also noticeable.
Positive results in the treatment of mesothelioma were also presented.